Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 5.21% |
| CYNOSURE INC | CYNO | 4.42% |
| DAWSON GEOPH | DWSN | 4.33% |
| MARRIOTT VAC | VAC | 3.27% |
| BLOOMIN' | BLMN | 2.93% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Yesterday, Tenet Healthcare Corp. (THC - Analyst Report) announced its projection of adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) to be within $1.2–1.3 billion.
Meanwhile, the adjusted EBITDA includes the deductions from accounting changes to affect some deferred income recognized out of certain Medicare Healthcare Information Technology (HIT) incentive payments, which is expected to be about $31 million in 2012.
In November last year, management had reiterated its adjusted EBITDA projection to be between $1.175 billion and $1.275 billion. The company expects the upside to appear from cost reduction through its ongoing Medicare Performance Initiative and an increase its physicians. The outlook also reflects a growth projection in Tenet’s Conifer service business.
The growth strategies discussed above are further expected to negate the adverse effects of government reimbursements and macro economic volatility. However, Tenet’s adjusted EBITDA dipped 3.9% year over year to $195 million in the third quarter of 2011.
Adjusted EBITDA is expected to weaken again in the fourth quarter of 2011, given the deferred recognition of revenues related to HIT incentive payments worth $12 million, which resulted from a change in the accounting method. Even an adverse affect of decline in interest rate is expected to hurt adjusted EBITDA by about $7 million.
However, these will be partially offset by a year-over-year hike in admissions and a flat growth in outpatient visits. Additionally, a net favorable impact of $28 million related to the California Provider Fee Six-Month program is also expected in the fourth quarter of 2011.
Earnings Review
In November last year, Tenet reported its third-quarter operating earnings of $16 million or 4 cents per share, beating the Zacks Consensus Estimate of 1 cent and operating loss of $14 million or 1 cent per share in the prior-year quarter.
The improved results were due to a growth in admissions, outpatient visits and surgeries, which were partly offset by the rise in bad debt and operating expenses.
The Zacks Consensus Estimate for fourth-quarter earnings is pegged at 14 cents per share, up about 41% from the year-ago quarter. For 2011, Tenet’s earnings are expected to be 42 cents per share, growing about 3% from 2010.
Management expects to announce its detailed growth guidance for 2012 on February 28, 2012, when the company is scheduled to release the results for its fourth quarter and full year 2011.
Tenet competes with HCA Inc. (HCA - Snapshot Report) and Community Health Systems Inc. (CYH - Snapshot Report). The company carries a Zacks #2 Rank, which implies a short-term Buy rating and a long term Outperform stance.
On Monday, the shares of Tenet closed at $5.10, up 2.2%, on the New York Stock Exchange.
Read the full reports :
Analyst Report on THC
Snapshot Report on CYH
Snapshot Report on HCA